Molecular Virus-Testing Platform Released in Europe

An automated branched DNA (bDNA) molecular system for viral-load testing of human immunodeficiency virus (HIV), hepatitis C virus (HCV), and hepatitis B virus (HBV) in serum and blood plasma is now available in Europe.

The system provides an easy-to-use molecular testing platform suitable for the general hospital and molecular laboratory. Its touch screen interface and complete "load and go” bDNA automation includes on-board temperature control of assay reagents, on-board preparation of several assay reagents, and automated delivery of all assay reagents to micro wells. These features significantly reduce hands-on time and improve workflow and testing flexibility for mid- to high-volume laboratories.

This new system, called Versant 440, was developed by Bayer Healthcare, Diagnostics Division (Tarrytown, NY, USA), which is a subsidiary of Bayer AG (Leverkusen, Germany). It can process 12-168 patient samples per run and is compatible with a laboratory information system (LIS) through the Bayer bi-directional interface. The system has received the CE Mark.

"This addition allows us to offer a more robust portfolio with complete bDNA automation to the molecular diagnostics marketplace in Europe,” said Tony Bihl, president, Bayer Diagnostics. "The Versant 440 system reinforces Bayer Diagnostics' focus on satisfying the needs of hospitals and molecular laboratories.”



Related Links:
Bayer Healthcare